Mostrar el registro sencillo del ítem
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BRANCHOUX, Sebastien | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SOFEU, Casimir Ledoux | |
| dc.contributor.author | GAUDIN, A. F. | |
| dc.contributor.author | KURT, M. | |
| dc.contributor.author | MOSHYK, A. | |
| dc.contributor.author | ITALIANO, A. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | RONDEAU, Virginie | |
| dc.date.accessioned | 2022-01-19T16:23:09Z | |
| dc.date.available | 2022-01-19T16:23:09Z | |
| dc.date.issued | 2021-12-17 | |
| dc.identifier.issn | 2059-7029 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/124442 | |
| dc.description.abstractEn | BACKGROUND: Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigated TNT-D as a surrogate endpoint (SE) for overall survival (OS) in previously untreated advanced melanoma patients. METHODS: Patient-level data from the 60-month results of the CheckMate 067 randomised, controlled trial were used. Analyses were carried out for nivolumab monotherapy or nivolumab with ipilimumab versus ipilimumab monotherapy. The SE 1-step validation method based on a joint frailty-copula model was used where the country of enrolment was applied to define clusters. Kendall's τ and the coefficient of determination (R(2)(trial)) were estimated for respective measurements of association at the individual and cluster levels. The surrogate threshold effect, the maximum threshold hazard ratio for TNT-D that would translate into OS benefit, was estimated. A leave-one-out cross-validation analysis was carried out to evaluate model robustness. RESULTS: Fifteen clusters of data were generated from 945 patients. For both nivolumab-containing arms, the association between TNT-D and OS was deemed acceptable at the individual level (Kendall's τ > 0.60) and strong at the cluster level, with R(2)(trial) fairly close to 1, with narrow confidence intervals. The estimated surrogate threshold effects were 0.61 for nivolumab versus ipilimumab and 0.49 for nivolimub + ipilimumab versus ipilimumab. Cross-validation results showed minimum variation of the correlation measures and satisfactory predictive accuracy for the model. CONCLUSION: Results suggest that TNT-D may be a valuable SE in previously untreated advanced melanoma patients treated with immune checkpoint inhibitors. Surrogacy analyses considering multiple randomised controlled trials are warranted for confirming these findings. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Immune checkpoint inhibitors | |
| dc.subject.en | Nivolumab | |
| dc.subject.en | Ipilimumab | |
| dc.subject.en | Surrogate endpoint | |
| dc.subject.en | Overall survival | |
| dc.subject.en | Time to next treatment | |
| dc.subject.en | Advanced melanoma | |
| dc.title.en | Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.esmoop.2021.100340 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34929616 | en_US |
| bordeaux.journal | ESMO Open | en_US |
| bordeaux.page | 100340 | en_US |
| bordeaux.volume | 7 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | |
| bordeaux.team | BIOSTAT_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Bristol-Myers Squibb | en_US |
| hal.identifier | hal-03535698 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-01-19T16:23:12Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=ESMO%20Open&rft.date=2021-12-17&rft.volume=7&rft.issue=1&rft.spage=100340&rft.epage=100340&rft.eissn=2059-7029&rft.issn=2059-7029&rft.au=BRANCHOUX,%20Sebastien&SOFEU,%20Casimir%20Ledoux&GAUDIN,%20A.%20F.&KURT,%20M.&MOSHYK,%20A.&rft.genre=article |
